Skip to main content
Erschienen in: Supportive Care in Cancer 1/2013

01.01.2013 | Special Article

Systematic review of oral cryotherapy for management of oral mucositis caused by cancer therapy

verfasst von: Douglas E. Peterson, Kerstin Öhrn, Joanne Bowen, Monica Fliedner, Judith Lees, Charles Loprinzi, Takehiko Mori, Anthony Osaguona, Dianna S. Weikel, Sharon Elad, Rajesh V. Lalla, For the Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO)

Erschienen in: Supportive Care in Cancer | Ausgabe 1/2013

Einloggen, um Zugang zu erhalten

Abstract

Purpose

This systematic review analyzed the strength of the literature and defined clinical practice guidelines for the use of oral cryotherapy for the prevention and/or treatment of oral mucositis caused by cancer therapy.

Methods

A systematic review on relevant oral cryotherapy studies indexed prior to 31 December 2010 was conducted by the Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society for Oral Oncology (MASCC/ISOO) using OVID/MEDLINE, with publications selected for review based on defined inclusion and exclusion criteria. Findings from the reviewed studies were integrated into guidelines based on the overall level of evidence for each intervention. Guidelines were classified into three types: recommendation, suggestion, or no guideline possible.

Results

Twenty-two clinical studies and two meta-analyses were analyzed. Results were compared with the MASCC/ISOO guidelines published in 2007. The recommendation for the use of oral cryotherapy to prevent oral mucositis in patients receiving bolus fluorouracil (5-FU) was maintained, in agreement with the 2007 guidelines. A suggestion for use of oral cryotherapy to prevent oral mucositis in patients receiving high-dose melphalan as conditioning regimen with or without total body irradiation for HCST was revised from the 2007 guidelines. No guideline was possible for any other intervention, due to insufficient evidence.

Conclusions

The evidence continues to support the use of oral cryotherapy for prevention of oral mucositis in patients receiving bolus 5-FU chemotherapy or high-dose melphalan. This intervention is consistent with the MASCC/ISOO guidelines published in 2007. The literature is limited by the fact that utilization of a double-blind study design is not feasible. Future studies that compare efficacy of oral cryotherapy with other mucositis agents in patients receiving chemotherapy with relatively short plasma half-lives would be useful.
Literatur
1.
Zurück zum Zitat Mahood DJ, Dose AM, Loprinzi CL, Veeder MH, Athmann LM, Therneau TM, Sorensen JM, Gainey DK, Mailliard JA, Gusa NL (1991) Inhibition of fluorouracil-induced stomatitis by oral cryotherapy. J Clin Oncol 9:449–452PubMed Mahood DJ, Dose AM, Loprinzi CL, Veeder MH, Athmann LM, Therneau TM, Sorensen JM, Gainey DK, Mailliard JA, Gusa NL (1991) Inhibition of fluorouracil-induced stomatitis by oral cryotherapy. J Clin Oncol 9:449–452PubMed
2.
Zurück zum Zitat Baydar M, Dikilitas M, Sevinc A, Aydogdu I (2005) Prevention of oral mucositis due to 5-fluorouracil treatment with oral cryotherapy. J Natl Med Assoc 97:1161–1164PubMed Baydar M, Dikilitas M, Sevinc A, Aydogdu I (2005) Prevention of oral mucositis due to 5-fluorouracil treatment with oral cryotherapy. J Natl Med Assoc 97:1161–1164PubMed
3.
Zurück zum Zitat Cascinu S, Fedeli A, Fedeli SL, Catalano G (1994) Oral cooling (cryotherapy), an effective treatment for the prevention of 5-fluorouracil-induced stomatitis. Eur J Cancer B Oral Oncol 30B:234–236PubMedCrossRef Cascinu S, Fedeli A, Fedeli SL, Catalano G (1994) Oral cooling (cryotherapy), an effective treatment for the prevention of 5-fluorouracil-induced stomatitis. Eur J Cancer B Oral Oncol 30B:234–236PubMedCrossRef
4.
Zurück zum Zitat Hudes GR, Lipsitz S, Grem J, Morrisey M, Weiner L, Kugler JW, Benson A 3rd (1999) A phase II study of 5-fluorouracil, leucovorin, and interferon-alpha in the treatment of patients with metastatic or recurrent gastric carcinoma: an Eastern Cooperative Oncology Group study (E5292). Cancer 85:290–294PubMedCrossRef Hudes GR, Lipsitz S, Grem J, Morrisey M, Weiner L, Kugler JW, Benson A 3rd (1999) A phase II study of 5-fluorouracil, leucovorin, and interferon-alpha in the treatment of patients with metastatic or recurrent gastric carcinoma: an Eastern Cooperative Oncology Group study (E5292). Cancer 85:290–294PubMedCrossRef
5.
Zurück zum Zitat Nikoletti S, Hyde S, Shaw T, Myers H, Kristjanson LJ (2005) Comparison of plain ice and flavoured ice for preventing oral mucositis associated with the use of 5 fluorouracil. J Clin Nurs 14:750–753PubMedCrossRef Nikoletti S, Hyde S, Shaw T, Myers H, Kristjanson LJ (2005) Comparison of plain ice and flavoured ice for preventing oral mucositis associated with the use of 5 fluorouracil. J Clin Nurs 14:750–753PubMedCrossRef
6.
Zurück zum Zitat Papadeas E, Naxakis S, Riga M, Kalofonos C (2007) Prevention of 5-fluorouracil-related stomatitis by oral cryotherapy: a randomized controlled study. Eur J Oncol Nurs 11:60–65PubMedCrossRef Papadeas E, Naxakis S, Riga M, Kalofonos C (2007) Prevention of 5-fluorouracil-related stomatitis by oral cryotherapy: a randomized controlled study. Eur J Oncol Nurs 11:60–65PubMedCrossRef
7.
Zurück zum Zitat Sorensen JB, Skovsgaard T, Bork E, Damstrup L, Ingeberg S (2008) Double-blind, placebo-controlled, randomized study of chlorhexidine prophylaxis for 5-fluorouracil-based chemotherapy-induced oral mucositis with nonblinded randomized comparison to oral cooling (cryotherapy) in gastrointestinal malignancies. Cancer 112:1600–1606PubMedCrossRef Sorensen JB, Skovsgaard T, Bork E, Damstrup L, Ingeberg S (2008) Double-blind, placebo-controlled, randomized study of chlorhexidine prophylaxis for 5-fluorouracil-based chemotherapy-induced oral mucositis with nonblinded randomized comparison to oral cooling (cryotherapy) in gastrointestinal malignancies. Cancer 112:1600–1606PubMedCrossRef
8.
Zurück zum Zitat Rocke LK, Loprinzi CL, Lee JK, Kunselman SJ, Iverson RK, Finck G, Lifsey D, Glaw KC, Stevens BA, Hatfield AK, Vaught NL, Bartel J, Pierson N (1993) A randomized clinical trial of two different durations of oral cryotherapy for prevention of 5-fluorouracil-related stomatitis. Cancer 72:2234–2238PubMedCrossRef Rocke LK, Loprinzi CL, Lee JK, Kunselman SJ, Iverson RK, Finck G, Lifsey D, Glaw KC, Stevens BA, Hatfield AK, Vaught NL, Bartel J, Pierson N (1993) A randomized clinical trial of two different durations of oral cryotherapy for prevention of 5-fluorouracil-related stomatitis. Cancer 72:2234–2238PubMedCrossRef
9.
Zurück zum Zitat Yokomizo H, Yoshimatsu K, Hashimoto M, Ishibashi K, Umehara A, Yoshida K, Fujimoto T, Watanabe K, Ogawa K (2004) Prophylactic efficacy of allopurinol ice ball for leucovorin/5-fluorouracil therapy-induced stomatitis. Anticancer Res 24:1131–1134PubMed Yokomizo H, Yoshimatsu K, Hashimoto M, Ishibashi K, Umehara A, Yoshida K, Fujimoto T, Watanabe K, Ogawa K (2004) Prophylactic efficacy of allopurinol ice ball for leucovorin/5-fluorouracil therapy-induced stomatitis. Anticancer Res 24:1131–1134PubMed
10.
Zurück zum Zitat Dreicer R, Propert KJ, Kuzel T, Kirkwood JM, O'Dwyer PJ, Loehrer PJ (1997) A phase II trial of edatrexate in patients with advanced renal cell carcinoma. An Eastern Cooperative Oncology Group study. Am J Clin Oncol 20:251–253PubMedCrossRef Dreicer R, Propert KJ, Kuzel T, Kirkwood JM, O'Dwyer PJ, Loehrer PJ (1997) A phase II trial of edatrexate in patients with advanced renal cell carcinoma. An Eastern Cooperative Oncology Group study. Am J Clin Oncol 20:251–253PubMedCrossRef
11.
Zurück zum Zitat Gandara DR, Edelman MJ, Crowley JJ, Lau DH, Livingston RB (1997) Phase II trial of edatrexate plus carboplatin in metastatic non-small-cell lung cancer: a Southwest Oncology Group study. Cancer Chemother Pharmacol 41:75–78PubMedCrossRef Gandara DR, Edelman MJ, Crowley JJ, Lau DH, Livingston RB (1997) Phase II trial of edatrexate plus carboplatin in metastatic non-small-cell lung cancer: a Southwest Oncology Group study. Cancer Chemother Pharmacol 41:75–78PubMedCrossRef
12.
Zurück zum Zitat Edelman MJ, Gandara DR, Perez EA, Lau D, Lauder I, Turrell C, Uhrich M, Meyers F (1998) Phase I trial of edatrexate plus carboplatin in advanced solid tumors: amelioration of dose-limiting mucositis by ice chip cryotherapy. Invest New Drugs 16:69–75PubMedCrossRef Edelman MJ, Gandara DR, Perez EA, Lau D, Lauder I, Turrell C, Uhrich M, Meyers F (1998) Phase I trial of edatrexate plus carboplatin in advanced solid tumors: amelioration of dose-limiting mucositis by ice chip cryotherapy. Invest New Drugs 16:69–75PubMedCrossRef
13.
Zurück zum Zitat Karagözoğlu S, Filiz Ulusoy M (2005) Chemotherapy: the effect of oral cryotherapy on the development of mucositis. J Clin Nurs 14:754–765PubMedCrossRef Karagözoğlu S, Filiz Ulusoy M (2005) Chemotherapy: the effect of oral cryotherapy on the development of mucositis. J Clin Nurs 14:754–765PubMedCrossRef
14.
Zurück zum Zitat Aisa Y, Mori T, Kudo M, Yashima T, Kondo S, Yokoyama A, Ikeda Y, Okamoto S (2005) Oral cryotherapy for the prevention of high-dose melphalan-induced stomatitis in allogeneic hematopoietic stem cell transplant recipients. Support Care Cancer 13:266–269PubMedCrossRef Aisa Y, Mori T, Kudo M, Yashima T, Kondo S, Yokoyama A, Ikeda Y, Okamoto S (2005) Oral cryotherapy for the prevention of high-dose melphalan-induced stomatitis in allogeneic hematopoietic stem cell transplant recipients. Support Care Cancer 13:266–269PubMedCrossRef
15.
Zurück zum Zitat Bhatt V, Vendrell N, Nau K, Crumb D, Roy V (2010) Implementation of a standardized protocol for prevention and management of oral mucositis in patients undergoing hematopoietic cell transplantation. J Oncol Pharm Pract 16:195–204PubMedCrossRef Bhatt V, Vendrell N, Nau K, Crumb D, Roy V (2010) Implementation of a standardized protocol for prevention and management of oral mucositis in patients undergoing hematopoietic cell transplantation. J Oncol Pharm Pract 16:195–204PubMedCrossRef
16.
Zurück zum Zitat Dumontet C, Sonnet A, Bastion Y, Salles G, Espinouse D, Coiffier B (1994) Prevention of high dose L-PAM-induced mucositis by cryotherapy. Bone Marrow Transplant 14:492–494PubMedCrossRef Dumontet C, Sonnet A, Bastion Y, Salles G, Espinouse D, Coiffier B (1994) Prevention of high dose L-PAM-induced mucositis by cryotherapy. Bone Marrow Transplant 14:492–494PubMedCrossRef
17.
Zurück zum Zitat Gori E, Arpinati M, Bonifazi F, Errico A, Mega A, Alberani F, Sabbi V, Costazza G, Leanza S, Borrelli C, Berni M, Feraut C, Polato E, Altieri MC, Pirola E, Loddo MC, Banfi M, Barzetti L, Calza S, Brignoli C, Bandini G, De Vivo A, Bosi A, Baccarani M (2007) Cryotherapy in the prevention of oral mucositis in patients receiving low-dose methotrexate following myeloablative allogeneic stem cell transplantation: a prospective randomized study of the Gruppo Italiano Trapianto di Midollo Osseo Nurses Group. Bone Marrow Transplant 39:347–352PubMedCrossRef Gori E, Arpinati M, Bonifazi F, Errico A, Mega A, Alberani F, Sabbi V, Costazza G, Leanza S, Borrelli C, Berni M, Feraut C, Polato E, Altieri MC, Pirola E, Loddo MC, Banfi M, Barzetti L, Calza S, Brignoli C, Bandini G, De Vivo A, Bosi A, Baccarani M (2007) Cryotherapy in the prevention of oral mucositis in patients receiving low-dose methotrexate following myeloablative allogeneic stem cell transplantation: a prospective randomized study of the Gruppo Italiano Trapianto di Midollo Osseo Nurses Group. Bone Marrow Transplant 39:347–352PubMedCrossRef
18.
Zurück zum Zitat Lilleby K, Garcia P, Gooley T, McDonnnell P, Taber R, Holmberg L, Maloney DG, Press OW, Bensinger W (2006) A prospective, randomized study of cryotherapy during administration of high-dose melphalan to decrease the severity and duration of oral mucositis in patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 37:1031–1035PubMedCrossRef Lilleby K, Garcia P, Gooley T, McDonnnell P, Taber R, Holmberg L, Maloney DG, Press OW, Bensinger W (2006) A prospective, randomized study of cryotherapy during administration of high-dose melphalan to decrease the severity and duration of oral mucositis in patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 37:1031–1035PubMedCrossRef
19.
Zurück zum Zitat Mori T, Aisa Y, Yamazaki R, Mihara A, Ikeda Y, Okamoto S (2006) Cryotherapy for the prevention of high-dose melphalan-induced oral mucositis. Bone Marrow Transplant 38:637–638PubMedCrossRef Mori T, Aisa Y, Yamazaki R, Mihara A, Ikeda Y, Okamoto S (2006) Cryotherapy for the prevention of high-dose melphalan-induced oral mucositis. Bone Marrow Transplant 38:637–638PubMedCrossRef
20.
Zurück zum Zitat Ohbayashi Y, Imataki O, Ohnishi H, Iwasaki A, Ogawa T, Inagaki N, Shigeta H, Ohue Y, Tasaka T, Kitanaka A, Kubota Y, Tanaka T, Ishida T, Miyake M (2008) Multivariate analysis of factors influencing oral mucositis in allogeneic hematopoietic stem cell transplantation. Ann Hematol 87:837–845PubMedCrossRef Ohbayashi Y, Imataki O, Ohnishi H, Iwasaki A, Ogawa T, Inagaki N, Shigeta H, Ohue Y, Tasaka T, Kitanaka A, Kubota Y, Tanaka T, Ishida T, Miyake M (2008) Multivariate analysis of factors influencing oral mucositis in allogeneic hematopoietic stem cell transplantation. Ann Hematol 87:837–845PubMedCrossRef
21.
Zurück zum Zitat Sato A, Saisho-Hattori T, Koizumi Y, Minegishi M, Iinuma K, Imaizumi M (2006) Prophylaxis of mucosal toxicity by oral propantheline and cryotherapy in children with malignancies undergoing myeloablative chemo-radiotherapy. Tohoku J Exp Med 210:315–320PubMedCrossRef Sato A, Saisho-Hattori T, Koizumi Y, Minegishi M, Iinuma K, Imaizumi M (2006) Prophylaxis of mucosal toxicity by oral propantheline and cryotherapy in children with malignancies undergoing myeloablative chemo-radiotherapy. Tohoku J Exp Med 210:315–320PubMedCrossRef
22.
Zurück zum Zitat Svanberg A, Birgegard G, Ohrn K (2007) Oral cryotherapy reduces mucositis and opioid use after myeloablative therapy—a randomized controlled trial. Support Care Cancer 15:1155–1161PubMedCrossRef Svanberg A, Birgegard G, Ohrn K (2007) Oral cryotherapy reduces mucositis and opioid use after myeloablative therapy—a randomized controlled trial. Support Care Cancer 15:1155–1161PubMedCrossRef
23.
Zurück zum Zitat Svanberg A, Ohrn K, Birgegard G (2010) Oral cryotherapy reduces mucositis and improves nutrition—a randomised controlled trial. J Clin Nurs 19:2146–2151PubMedCrossRef Svanberg A, Ohrn K, Birgegard G (2010) Oral cryotherapy reduces mucositis and improves nutrition—a randomised controlled trial. J Clin Nurs 19:2146–2151PubMedCrossRef
24.
Zurück zum Zitat Stokman MA, Spijkervet FK, Boezen HM, Schouten JP, Roodenburg JL, de Vries EG (2006) Preventive intervention possibilities in radiotherapy- and chemotherapy-induced oral mucositis: results of meta-analyses. J Dent Res 85:690–700PubMedCrossRef Stokman MA, Spijkervet FK, Boezen HM, Schouten JP, Roodenburg JL, de Vries EG (2006) Preventive intervention possibilities in radiotherapy- and chemotherapy-induced oral mucositis: results of meta-analyses. J Dent Res 85:690–700PubMedCrossRef
25.
Zurück zum Zitat Worthington HV, Clarkson JE, Bryan G, Furness S, Glenny AM, Littlewood A, McCabe MG, Meyer S, Khalid T (2010) Interventions for preventing oral mucositis for patients with cancer receiving treatment. Cochrane Database System Rev: CD000978 Worthington HV, Clarkson JE, Bryan G, Furness S, Glenny AM, Littlewood A, McCabe MG, Meyer S, Khalid T (2010) Interventions for preventing oral mucositis for patients with cancer receiving treatment. Cochrane Database System Rev: CD000978
26.
Zurück zum Zitat Keefe DM, Schubert MM, Elting LS, Sonis ST, Epstein JB, Raber-Durlacher JE, Migliorati CA, McGuire DB, Hutchins RD, Peterson DE (2007) Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer 109:820–831PubMedCrossRef Keefe DM, Schubert MM, Elting LS, Sonis ST, Epstein JB, Raber-Durlacher JE, Migliorati CA, McGuire DB, Hutchins RD, Peterson DE (2007) Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer 109:820–831PubMedCrossRef
28.
Zurück zum Zitat Grant SC, Kris MG, Young CW, Sirotnak FM (1993) Edatrexate, an antifolate with antitumor activity: a review. Cancer Invest 11:36–45PubMedCrossRef Grant SC, Kris MG, Young CW, Sirotnak FM (1993) Edatrexate, an antifolate with antitumor activity: a review. Cancer Invest 11:36–45PubMedCrossRef
29.
30.
Zurück zum Zitat Elad S, Bowen J, Zadik Y, Lalla RV (2012) Development of the MASCC/ISOO mucositis guidelines: considerations underlying the process. Support Care Cancer. doi:10.1007/s00520-012-1593-6 Elad S, Bowen J, Zadik Y, Lalla RV (2012) Development of the MASCC/ISOO mucositis guidelines: considerations underlying the process. Support Care Cancer. doi:10.​1007/​s00520-012-1593-6
31.
Zurück zum Zitat Somerfield MR, Padberg JJ, Pfister DG, Bennett CL, Recht A, Smith TJ, Weeks JC, Winn RJ, Durant JR (2000) ASCO clinical practice guidelines: process, progress, pitfalls, and prospects. Class Pap Curr Comment 4:881–886 Somerfield MR, Padberg JJ, Pfister DG, Bennett CL, Recht A, Smith TJ, Weeks JC, Winn RJ, Durant JR (2000) ASCO clinical practice guidelines: process, progress, pitfalls, and prospects. Class Pap Curr Comment 4:881–886
32.
Zurück zum Zitat Hadorn DC, Baker D, Hodges JS, Hicks N (1996) Rating the quality of evidence for clinical practice guidelines. J Clin Epidemiol 49:749–754PubMedCrossRef Hadorn DC, Baker D, Hodges JS, Hicks N (1996) Rating the quality of evidence for clinical practice guidelines. J Clin Epidemiol 49:749–754PubMedCrossRef
Metadaten
Titel
Systematic review of oral cryotherapy for management of oral mucositis caused by cancer therapy
verfasst von
Douglas E. Peterson
Kerstin Öhrn
Joanne Bowen
Monica Fliedner
Judith Lees
Charles Loprinzi
Takehiko Mori
Anthony Osaguona
Dianna S. Weikel
Sharon Elad
Rajesh V. Lalla
For the Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO)
Publikationsdatum
01.01.2013
Verlag
Springer-Verlag
Erschienen in
Supportive Care in Cancer / Ausgabe 1/2013
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-012-1562-0

Weitere Artikel der Ausgabe 1/2013

Supportive Care in Cancer 1/2013 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.